CLOs on the Move

Mylan

www.mylan.com

 
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.mylan.com
  • 1000 Mylan Boulevard
    Canonsburg, PA USA 15317
  • Phone: 724.514.1800

Executives

Name Title Contact Details
David Bayles
 Chief Administrative and Compliance Officer Profile
Brian Roman
 Global General Counsel Profile
Paul Feuerman
 General Counsel, Rest of World/Expansion Markets Profile
Joellen Dillon
 Chief Legal Officer Profile

Similar Companies

Hi-Tech Pharmacal Co Inc

Hi-Tech Pharmacal Co Inc is a Amityville, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Fairfax Behavioral Health

WRS

Acumen Pharmaceuticals

Acumen Pharmaceuticals is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.